R&D Convention
DNDi welcomes the CEWG report on coordination and financing of R&D for the health needs of developing countries and the forthcoming discussions at the World Health Assembly in May. More
LONDON NTD EVENT
Key lessons learned by DNDi in the last decade to boost innovation. Watch Bernard Pécoul’s speech in a Webcast. More
SLEEPING SICKNESS
SCYX-7158 enters Phase I clinical study. A drug candidate from the oxaboroles chemical class, SCYX-7158 is the first new oral drug candidate discovered specifically to combat human African trypanosomiasis. More
CHAGAS DISEASE
DNDi recently started recruiting patients for three new clinical studies on diagnosis and treatment of Chagas disease in Argentina and Bolivia. More
LEISHMANIASIS
SSG&PM, a new shorter course, cost-effective treatment for visceral leishmaniasis, is recommended by the WHO as first-line treatment in East Africa. Implementation has commenced in Sudan and South Sudan. More
MALARIA
100 million treatments of ASAQ, DNDi’s antimalarial combination therapy of Artesunate and Amodiaquine, have been distributed in 31 countries since its launch in 2007 ! More
PAEDIATRIC HIV
MSF podcast: ''Children with HIV need more treatment options; DNDi aims to help fill the void.'' More
SCYNEXIS Inc. as part of the DNDi HAT Lead Optimization Consortium
Screening and optimization of specific chemical series against human African Trypanosomiasis (HAT): 4926 compounds
DNDi Lead Optimization Consortium (Epichem, Murdoch University, CDCO):
Optimization of fenarimol series for the treatment of Chagas disease: 751 compounds
PORTFOLIO
Current portfolio:Working in partnership with industry and academia, DNDi has built the largest ever R&D portfolio for the kinetoplastid diseases.
New disease areas:
DNDi has decided to take on two new mini-portfolios: paediatric HIV and helminth infections.
PUBLICATIONS
VL: contraceptive use after milteflosine treatment"Translational pharmacokinetic modelling and simulation for the assessment of duration of contraceptive use after treatment with milteflosine" by Balasegaram et alii, JAC, 2012 May
ASAQ in India
"Artesunate-amodiaquine fixed dose combination for the treatment of Plasmodium falsiparum malaria in India" by Bhawna Sharma et alii, Malaria Journal. 2012 March
ASAQ in sub-Saharan Africa
"Comparing changes in haematologic parameters occuring in patients included in randomized controlled trials of artesunate-amodiaquine vs single and combination treatments of uncomplicated falsiparum in sub-Saharan Africa" by Julien Zwang et alii, Malaria Journal. 2012 January
Visceral Leishmaniasis treatment
"Visceral Leishmaniasis treatment: what do we have, what do we need and how do we deliver it?" by Eric Chatelain, Lucio H. Fretas-Junior et alii, International Journal for Parasitology. 2011 December
DNDi model: status and challenges
"Drugs for Neglected Diseases initiative model of drug development for neglected diseases: current status and future challenges" by Shing Chang and Jean-Robert Ioset Future Medicinal Chemistry. 2011 September
June 13-16, 2012
15th ICID
Bangkok, Thailand
DNDi will present a poster on ASMQ partnerships
May 21-26, 2012
65th World Health Assembly
Geneva, Switzerland
More on the event and the CEWG report
April 24-26, 2012
Forum 2012
Cohred / Global Forum for Health Research
Cape Town, South Africa
More information on the meeting
April 18-21, 2012
Geneva Health Forum
Geneva, Switzerland
DNDi and MSF will co-host a session on adult chronic Chagas disease.
Jan 30, 2012
Uniting to Combat Neglected Tropical Diseases
London, UK
On the occasion of the high-level event, DNDi welcomed the commitments from various partners and emphasized that filling major gaps in R&D are urgently needed to develop new treatments for neglected patients.
DNDI NEWS
DNDi in the Media
Except where otherwise noted, content on this site is licensed under
a Creative Commons Attribution-Noncommercial-Share Alike 2.5 Switzerland License